Humacyte
HUMA
159 hedge funds and large institutions have $35.9M invested in Humacyte in 2026 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 29 reducing their positions, and 19 closing their positions.
206% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $397K
86% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 29
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
8% more funds holding
Funds holding: 147 → 159 (+12)
1.99% more ownership
Funds ownership: 29.54% → 31.53% (+2%)
32% less capital invested
Capital invested by funds: $53.1M → $35.9M (-$17.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Antipodes Partners
Royal Exchange,
Australia
|
+$5.94M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.9M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.97M |
| 4 |
BlackRock
New York
|
+$1.01M |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.62M |
| 2 |
Morgan Stanley
New York
|
-$2.41M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.63M |
| 4 |
Two Sigma Investments
New York
|
-$1.37M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.1M |
HUMA Hedge Fund Activity: Q1 2026 in Review
159 of the 8,180 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2026, worth a combined $35.9M — down 32% from $53.1M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new HUMA positions and 19 closed out — a net gain of 16 holders — while 54 added to existing stakes and 29 trimmed.
The largest buyer was Antipodes Partners, adding an estimated $5.94M. The largest seller was Millennium Management, cutting an estimated $2.62M.
- 159 institutional investors held Humacyte (HUMA) as of Q1 2026, up from 147 in Q4 2025.
- Funds reported $35.9M of Humacyte stock for Q1 2026, down 32% quarter-over-quarter.
- 35 funds opened new Humacyte positions in Q1 2026 and 19 closed out, a net change of +16 holders.
- The largest Humacyte buyer in Q1 2026 was Antipodes Partners, an estimated $5.94M added.
- The largest Humacyte seller in Q1 2026 was Millennium Management, an estimated $2.62M sold.
Based on aggregated 13F filings for Q1 2026.